The therapeutic strategies targeting the NLRP3 inflammasome for PD treatment include inhibitors of the NLRP3 inflammatory pathways, mitochondria-focused treatments, microRNAs, and other therapeutic compounds. This evidence concerns the gene NLRP3 and Parkinson disease.